OakChart

Universe Pharmaceuticals INC

UPCHealthcare·Drug Manufacturers - Specialty & Generic·China·Nano·NASD·Nov 13 • 6:39 AM ET

1.530.00 (0.00%)
2026-11-13 13:34 CET
Market cap
$7.69M
Revenue, TTM
17.74 USD m
Net income, TTM
-1.94 USD m
Free cash flow, TTM
-12.39 USD m
EPS diluted, TTM
-3.45
Price / earnings
-
Compare

Price

UPC against its 20, 50 and 200-day averages
Terms2050200
Patternshover a marker to name it
RS 05.0010.0015.0027.6M55.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26UPCclose 1.5320-day 2.2650-day 3.54200-day 3.681.5352w high 17.9652-week range, not 6 months

91.5% under the 52-week high of 17.96 on 29 Jun 2026. 52-week low 1.33 on 6 Nov 2026. Last 15 sessions, 239.1% high to low

Volume 0.03× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 1 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%)
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: Return on Equity: Over +15% — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

UPC
52-week range, 1% of the way up
1.3317.96

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Employees216
IPOMar 23, 2021
Beta1.85
ATR, 14d0.32
Rel volume0.03
Short float7.77%
Insider own89.18%
Inst own1.94%

Snapshot

6 groups

Valuation

Index-
Market Cap$7.69M
Enterprise Value-11.81M
Income-1.94M
Sales17.74M
Book / share98.78
Cash / share5.78
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees216
IPOMar 23, 2021

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales0.43
Price / book0.02
Price / cash0.26
Price / free cash flow-
Value / cash profit-
Value / sales-0.67
Quick Ratio3.75
Current Ratio4.05
Debt / equity0.17
Long-term debt / equity0.04
Options and shortNo / Yes

Earnings

Earnings / share-3.45
Earnings next year-
Earnings next quarter-
Earnings this year-
Earnings next year-
Earnings growth, 5 years-
Past earnings growth82.27% -
Past sales growth-23.66% -10.27%
Earnings vs last year-100.01%
Sales vs last year-8.04%
Earnings vs last quarter70.78%
Sales vs last quarter-1.28%
Earnings-
Surprise- -

Ownership

Insiders own89.18%
Insider trades0.00%
Institutions own1.94%
Institution trades87.00%
Return on assets-2.55%
Return on equity-3.50%
Return on capital-3.36%
Gross Margin35.86%
Operating margin-11.78%
Profit Margin-10.95%
20-day average-32.45%
50-day average-56.84%
200-day average-58.42%

Technical

Shares out0.56M
Shares floating0.54M
Short / float7.77%
Short ratio0.24
Short interest0.04M
52-week high17.96 -91.5%
52-week low1.33 +15.0%
Volatility11.45% 17.38%
Average range0.32
Strength index27.11
Market sensitivity1.85
Relative volume0.03
Avg Volume175.11K
Volume285

Performance

Perf Week10.07%
Perf Month-63.13%
Perf Quarter-73.53%
Perf Half Y-44.57%
Perf YTD-59.84%
Perf Year-59.09%
Perf 3Y-99.76%
Perf 5Y-99.98%
Perf 10Y-
Recommendation-
Target Price-
Prev Close1.53
Price1.53
Change %0.00%

Peers

Mkt cap
TickerCompanyMkt cap
SXTCChina SXT Pharmaceuticals Inc2.03M
CPHIChina Pharma Holdings Inc21.75M
RGCRegencell Bioscience Holdings Ltd2.55B
ZYBTZhengye Biotechnology Holding Ltd44.61M
HKPDCellyan Biotechnology Co Ltd3.72M
ZCMDZhongchao Inc4.31M
ITOCiTonic Holdings Ltd16.24M
WOKWork Medical Technology Group Ltd5.71M
AHGAkso Health Group ADR1.15B
ZJYLJin Medical International Ltd571.08M

News

latest 14 of 90

Quarterly earnings

actual against estimate

The earnings feed came back with no quarters.

Annual earnings

The earnings feed came back with no years.

Estimate revisions

Latest snapshot of each period and type.

No estimate revisions.

Estimate history

Annual
Metric20182019202020212022202320242025
EPS per share1303.3441294.5241295.7121873.656-1446.048-653527.671-376176.617-8.055
Sales USD millions2933314840322318
Shares million shares00000001

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY9/30/20252024FY9/30/20242023FY9/30/20232022FY9/30/20222021FY9/30/20212020FY9/30/20202019FY9/30/20192018FY9/30/2018
Total Revenue17.7417.86-22.4%23.02-28.8%32.31-19.5%40.14-16.3%47.98+56.3%30.70-7.6%33.23+16.6%28.51
Cost of Goods Sold Incl. D&A11.3811.98-30.3%17.20-22.6%22.23+20.4%18.46-19.2%22.85+35.9%16.81-16.2%20.05+30.5%15.36
Gross Profit6.365.88+1.0%5.82-42.3%10.08-53.5%21.69-13.7%25.14+81.0%13.89+5.4%13.18+0.2%13.15
Selling, General and Administrative Excl. Other8.448.80-35.3%13.60-1.9%13.86-52.1%28.92+155.5%11.32+225.3%3.48+4.5%3.33-1.8%3.39
Research and Development0.660.50-83.3%2.99-38.0%4.82-36.7%7.62+39.8%5.45+856.1%0.57-5.0%0.60-21.1%0.76
Other Operating Expense0.010.00-100.0%0.25+38.9%0.18-14.3%0.21-4.5%0.22+37.5%0.16+60.0%0.100.0%0.10
Operating Income-2.09-2.92-8.02-3.97-7.44-154.7%13.59+32.6%10.25+5.1%9.75+0.9%9.66
Interest Expense0.230.23-17.9%0.28+75.0%0.160.0%0.16+60.0%0.10-16.7%0.12-7.7%0.13-18.8%0.16
Unusual Expense0.480.480.000.000.000.000.000.000.00
Net Income Before Taxes-2.01-3.74-8.15-4.36-8.02-158.8%13.65+35.4%10.08+4.7%9.63+1.4%9.50
Income Taxes0.000.00-100.0%0.61-72.9%2.25+200.0%0.75-68.2%2.36-7.1%2.54+21.0%2.10+9.4%1.92
Consolidated Net Income-1.94-3.67-8.73-6.58-8.74-177.2%11.32+49.7%7.56+0.1%7.55-0.7%7.60
Net Income From Continuing Operations-1.94-3.67-8.73-6.58-8.74-177.2%11.32+49.7%7.56+0.1%7.55-0.7%7.60
Net Income-1.94-3.67-8.73-6.58-8.74-177.2%11.32+49.7%7.56+0.1%7.55-0.7%7.60
EPS (Recurring) per share-2.85-7.32-376,176.62-653,527.67-1,446.05-177.2%1,873.65+44.6%1,295.70+0.1%1,294.54-0.7%1,303.36
EPS (Basic, Before Extraordinaries) per share-3.45-8.05-376,176.62-653,527.67-1,446.05-177.2%1,873.66+44.6%1,295.71+0.1%1,294.52-0.7%1,303.34
EPS (Diluted) per share-3.45-8.05-376,176.62-653,527.67-1,446.05-177.2%1,873.66+44.6%1,295.71+0.1%1,294.52-0.7%1,303.34
EBITDA-1.61-2.40-7.53-3.46-6.90-149.1%14.04+31.7%10.66+4.8%10.17+0.6%10.11
Non-Operating Income (Expense)0.79-0.11-173.3%0.15-0.24-0.42-362.5%0.16-0.050.00-100.0%0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Price To Earnings Ratio ratio statement ratio, not the snapshot-----2,847.54---
Price To Sales Ratio ratio0.090.110.000.000.311.12---
Gross Margin %35.8632.9325.2931.1954.0252.3845.2439.6746.12
Operating Margin %-11.78-16.33-34.83-12.28-18.5328.3233.3929.3533.87
Net Margin %-10.95-20.56-37.90-20.37-21.7623.5924.6222.7326.66
Shares Outstanding million shares0.560.560.000.00-100.0%0.010.0%0.010.0%0.010.0%0.010.0%0.01
Market Capitalization7.697.69-99.8%3,461.77+66.6%2,078.20-95.3%44,239.50-77.1%193,401.00+4.7%184,788.00--

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026S13/31/20262025S29/30/20252025S13/31/20252024S29/30/20242024S13/31/20242023S29/30/20232023S13/31/20232022S29/30/2022
Total Revenue9.048.719.1510.1412.8813.8418.4715.94
Cost of Goods Sold Incl. D&A5.815.575.997.569.649.7812.457.89
Gross Profit3.233.143.162.583.244.066.018.05
Selling, General and Administrative Excl. Other4.723.735.498.674.937.635.8018.06
Research and Development0.090.570.102.920.072.572.257.49
Other Operating Expense0.010.000.000.190.060.110.070.13
Operating Income-1.50-0.59-2.33-6.28-1.74-3.680.15-10.14
Interest Expense0.130.100.130.140.140.080.070.07
Unusual Expense0.000.480.00-7.627.620.000.000.00
Net Income Before Taxes-1.55-0.45-3.284.28-12.44-4.140.26-11.33
Income Taxes0.000.000.00-0.060.671.340.97-0.83
Consolidated Net Income-1.55-0.39-3.284.37-13.10-5.45-0.72-10.47
Net Income From Continuing Operations-1.55-0.39-3.284.37-13.10-5.45-0.72-10.47
Net Income-1.55-0.39-3.284.37-13.10-5.45-0.72-10.47
EPS (Recurring) per share-2.76-0.09-9.44-13,406.14-1,278.54-901.68-118.42-1,732.68
EPS (Basic, Before Extraordinaries) per share-2.76-0.69-9.4461,205.58-2,156.04-901.68-118.40-1,732.68
EPS (Diluted) per share-2.76-0.69-9.4461,205.58-2,156.04-901.68-118.40-1,732.68
EBITDA-1.27-0.34-2.06-6.04-1.49-3.430.41-9.90
Non-Operating Income (Expense)0.070.72-0.833.09-2.94-0.380.18-1.12
Price To Sales Ratio ratio0.090.130.070.000.300.110.370.31
Gross Margin %35.7036.0334.5725.4325.1829.3632.5750.52
Operating Margin %-16.60-6.77-25.42-61.93-13.51-26.560.81-63.61
Net Margin %-17.21-4.45-35.8943.14-101.68-39.36-3.87-65.67
Shares Outstanding million shares0.560.560.560.000.010.010.010.01
Market Capitalization7.692.370.893,461.774,790.802,078.2045,570.6044,239.50

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY9/30/20252024FY9/30/20242023FY9/30/20232022FY9/30/20222021FY9/30/20212020FY9/30/20202019FY9/30/20192018FY9/30/2018
Cash & Short Term Investments33.59+13.9%29.50+457.7%5.29-72.0%18.86-13.5%21.80+116.7%10.06+216.4%3.18-48.6%6.19
Short Term Receivables13.19-29.0%18.57+42.8%13.00-14.4%15.18-4.0%15.81+45.4%10.87+69.3%6.42-16.0%7.64
Inventories4.68+72.1%2.72-22.7%3.52+58.6%2.22-57.3%5.20+172.3%1.91-27.1%2.62-67.7%8.12
Other Current Assets2.14+151.8%0.85-75.4%3.46-34.0%5.24-31.7%7.670.00-100.0%0.02+100.0%0.01
Total Current Assets53.60+3.8%51.64+104.4%25.27-39.1%41.51-17.8%50.48+121.0%22.84+86.8%12.23-44.3%21.96
Net Property, Plant & Equipment14.70-4.2%15.34+2.3%14.99-5.3%15.83-11.4%17.87+303.4%4.43-3.1%4.57-10.0%5.08
Total Investments and Advances0.70-1.4%0.71+2.9%0.69-1.4%0.70-5.4%0.74+1.4%0.73+4.3%0.70-4.1%0.73
Intangible Assets0.30+15.4%0.26+73.3%0.15-6.3%0.16-11.1%0.18+5.9%0.170.0%0.17-5.6%0.18
Deferred Tax Assets-0.00-100.0%0.60-55.6%1.35+55.2%0.87+357.9%0.19+11.8%0.17+21.4%0.14
Other Assets0.000.00-100.0%0.040.000.00-100.0%0.440.000.00
Total Assets69.30+2.0%67.95+62.9%41.72-29.9%59.54-15.1%70.14+143.5%28.80+61.4%17.84-36.5%28.08
Short Term Debt Incl. Current Port. of LT Debt9.26+58.0%5.86+6.9%5.48+39.1%3.94-9.0%4.33+63.4%2.65+5.2%2.52-3.8%2.62
Accounts Payable1.67-66.0%4.91+7.0%4.59+49.0%3.08-42.0%5.31+97.4%2.69+38.7%1.94-34.0%2.94
Income Tax Payable-1.02+137.2%0.43+152.9%0.17-84.5%1.10-17.3%1.33+141.8%0.55-38.2%0.89
Other Current Liabilities2.25-73.6%8.52+162.2%3.25-45.1%5.92+1187.0%0.46-65.4%1.33+202.3%0.44-96.3%11.94
Total Current Liabilities13.17-35.2%20.31+47.7%13.75+5.0%13.10+16.9%11.21+40.1%8.00+46.8%5.45-70.4%18.40
Long Term Debt0.00-100.0%2.140.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities13.17-41.3%22.45+63.3%13.75+5.0%13.10+16.9%11.21+40.1%8.00+46.8%5.45-70.4%18.40
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity56.13+23.4%45.50+62.7%27.97-39.8%46.44-21.2%58.93+183.3%20.80+68.0%12.38+27.9%9.68
Total Shareholders Equity56.13+23.4%45.50+62.7%27.97-39.8%46.44-21.2%58.93+183.3%20.80+68.0%12.38+27.9%9.68
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity56.13+23.4%45.50+62.7%27.97-39.8%46.44-21.2%58.93+183.3%20.80+68.0%12.38+27.9%9.68
Total Liabilities & Stockholders Equity69.30+2.0%67.95+62.9%41.72-29.9%59.54-15.1%70.14+143.5%28.80+61.4%17.84-36.5%28.08
Book Value Per Share per share99.64-100.0%636,701.57-77.0%2,768,408.27+35914.2%7,687.00-21.2%9,754.65+173.5%3,566.21+68.0%2,122.98+27.9%1,659.70
Tangible Book Value Per Share per share99.11-100.0%633,023.24-77.0%2,753,701.84+35844.7%7,660.94-21.2%9,725.11+175.0%3,536.25+68.9%2,093.56+28.6%1,628.23
Full-Time Employees people216-4.0%2250.0%225+0.4%224-14.8%263+369.6%56--
Price to Book Ratio ratio0.0219.9643.84158.76546.94607.57--
Return on Assets %-5.35-14.40-13.00-13.4722.8832.4132.89-
Return on Equity %-7.23-20.53-17.69-16.5828.3945.5568.45-
Return on Invested Capital %-6.54-18.32-23.53-18.8119.2136.3360.9878.53
Quick Ratio ratio3.712.411.583.004.042.621.760.75
Current Ratio ratio4.072.541.843.174.502.852.241.19

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY9/30/20252024FY9/30/20242023FY9/30/20232022FY9/30/20222021FY9/30/20212020FY9/30/20202019FY9/30/20192018FY9/30/2018
Net Income-1.94-3.67-8.73-6.58-8.74-177.2%11.32+49.7%7.56+0.1%7.55-0.7%7.60
Depreciation0.480.52+6.1%0.49-3.9%0.51-3.8%0.53+17.8%0.45+9.8%0.41-2.4%0.42-6.7%0.45
Other Funds (Non Cash)0.370.37+94.7%0.19-0.05-111.4%0.44-0.23-1250.0%0.02-81.8%0.11-0.09
Funds from Operations-1.09-2.78-7.45-4.55-8.37-177.0%10.87+36.2%7.98-0.7%8.04+0.6%7.99
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-10.82-2.27-2.06-136.3%5.67-14.0%6.59-12.69-1.87-136.2%5.16-3.53
Income Taxes Payable0.54-0.32-158.2%0.55+96.4%0.28-0.90-0.30-141.1%0.73-0.32-172.7%0.44
Cash from Operating Activities-11.91-5.05-9.51-949.1%1.12-1.78-1.82-129.7%6.12-53.6%13.20+196.0%4.46
Capital Expenditures-0.54-0.35-0.36-0.04-0.09-13.53-0.05-0.09-0.15
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.010.000.000.000.000.000.000.00
Purchase or Sale of Investments-1.490.000.000.000.00-13.530.000.000.00
Purchase of Investments-1.490.000.000.000.00-15.330.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00-100.0%1.800.000.000.00
Other Uses0.000.000.000.00-3.810.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.02-0.34-0.36-0.04-3.91-27.06-0.05-0.09-0.15
Cash Dividends Paid0.000.000.000.000.000.000.00-16.01-3.06
Change in Capital Stock-0.0015.00-40.0%25.000.000.00-100.0%28.750.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-0.0015.00-40.0%25.000.000.00-100.0%28.750.000.000.00
Proceedsfrom Stock Options-0.0015.00-40.0%25.000.000.00-100.0%28.750.000.000.00
Issuance or Reduction of Debt, Net-5.42-5.27-158.9%8.95-1.39-141.9%3.32+435.5%0.62-31.9%0.910.00-1.85
Change in Long Term Debt--0.000.000.000.000.000.000.00
Issuance of Long Term Debt--0.000.000.000.000.000.000.00
Reduction of Long Term Debt--0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-2.79-0.440.000.00
Other Financing Activities Uses0.000.000.000.000.00-2.79-0.440.000.00
Cash from Financing Activities-6.829.73-71.3%33.95-1.39-141.9%3.32-87.5%26.58+5555.3%0.47-16.00-4.91
Exchange Rate Effect1.04-0.24-284.6%0.13-0.11-0.46-183.6%0.55+57.1%0.35-0.13-0.19
Net Change in Cash-19.714.09-83.1%24.21-0.43-2.84-1.74-125.3%6.88-3.01-0.79
Free Cash Flow-12.39-5.32-9.75-1011.2%1.07-1.88-15.35-353.3%6.06-53.8%13.12+204.4%4.31
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow ratio---0.01-----
Deferred Taxes & Investment Tax Credit-0.00-100.0%0.61-61.1%1.57-0.61-0.67-0.01-0.04-300.0%0.02

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026S13/31/20262025S29/30/20252025S13/31/20252024S29/30/20242024S13/31/20242023S29/30/20232023S13/31/20232022S29/30/2022
Cash & Short Term Investments29.0533.5947.2729.5011.3918.5026.2718.86
Short Term Receivables20.4613.1913.5318.5714.3810.7317.5215.18
Inventories3.984.684.192.723.763.523.082.22
Other Current Assets1.722.140.040.854.004.055.655.24
Total Current Assets55.2153.6065.0351.6433.5336.8152.5241.51
Net Property, Plant & Equipment15.2214.7014.6915.3414.9614.9916.1315.83
Total Investments and Advances0.720.700.690.710.690.690.730.70
Intangible Assets0.310.300.270.260.150.150.160.16
Deferred Tax Assets---0.000.000.660.831.35
Other Assets0.000.000.000.000.100.000.000.00
Total Assets71.4769.3080.6767.9549.4353.2970.3759.54
Short Term Debt Incl. Current Port. of LT Debt7.389.265.665.864.435.484.083.94
Accounts Payable3.751.677.404.917.764.5911.243.08
Income Tax Payable0.66-0.121.020.170.430.330.17
Other Current Liabilities1.862.2510.238.528.243.257.605.92
Total Current Liabilities13.6513.1723.4220.3120.6113.7523.2413.10
Long Term Debt2.170.002.072.142.080.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities15.8213.1725.4822.4522.6913.7523.2413.10
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity55.6556.1355.1845.5026.7439.5347.1346.44
Total Shareholders Equity55.6556.1355.1845.5026.7439.5347.1346.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity55.6556.1355.1845.5026.7439.5347.1346.44
Total Liabilities & Stockholders Equity71.4769.3080.6767.9549.4353.2970.3759.54
Book Value Per Share per share98.7899.6497.96636,701.574,401.146,543.347,800.297,687.00
Tangible Book Value Per Share per share98.2399.1197.49633,023.244,376.856,518.757,773.737,660.94
Price to Book Ratio ratio0.020.040.5619.96120.4943.84161.16158.76
Return on Assets %-2.55-5.351.67-14.40-30.97-10.92-15.78-13.47
Return on Equity %-3.50-7.232.66-20.53-50.22-14.34-20.66-16.58
Return on Invested Capital %-2.69-0.69-5.749.18-45.46-13.78-1.52-22.54
Quick Ratio ratio3.753.712.602.411.442.422.133.00
Current Ratio ratio4.054.072.782.541.632.682.263.17

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026S13/31/20262025S29/30/20252025S13/31/20252024S29/30/20242024S13/31/20242023S29/30/20232023S13/31/20232022S29/30/2022
Net Income-1.55-0.39-3.284.37-13.10-5.45-0.72-10.47
Depreciation0.230.250.270.240.250.250.260.24
Other Funds (Non Cash)0.000.370.00-10.2310.41-0.24-0.251.05
Funds from Operations-1.320.23-3.02-5.67-1.78-5.31-0.15-9.68
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.97-7.845.58-1.40-0.651.674.951.78
Income Taxes Payable-0.010.55-0.870.82-0.270.130.15-0.75
Cash from Operating Activities-4.30-7.612.56-7.08-2.43-3.644.80-7.90
Capital Expenditures-0.32-0.21-0.13-0.30-0.07-0.04-0.00-0.04
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.010.000.000.000.000.00-0.00
Purchase or Sale of Investments-1.490.000.000.000.000.000.000.00
Purchase of Investments-1.490.000.000.31-0.310.000.000.00
Sale Or Maturity of Investments0.000.000.00-0.310.310.000.000.00
Other Uses0.000.000.000.000.000.000.00-3.81
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.81-0.21-0.13-0.29-0.07-0.04-0.00-3.85
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock0.00-0.0015.0025.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.00-0.0015.0025.000.000.000.000.00
Proceedsfrom Stock Options0.00-0.0015.0025.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.15-6.671.402.896.07-3.472.083.34
Change in Long Term Debt-----0.000.000.00
Issuance of Long Term Debt-----0.000.000.00
Reduction of Long Term Debt-----0.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities-0.15-6.6716.4027.896.07-3.472.083.34
Exchange Rate Effect0.230.81-1.050.120.01-0.480.36-0.58
Net Change in Cash-6.03-13.6817.7820.643.58-7.637.24-9.00
Free Cash Flow-4.61-7.782.46-7.26-2.50-3.684.80-7.94
Price to Free Cash Flow ratio-----3.09--

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
Revenue From Sales Of Selfmanufactured TCMDProducts14,026.0513,260.65-5.5%74.3%
Revenue From Sales Of Thirdparty Products8,998.414,598.08-48.9%25.7%
Total23,024.4617,858.73-22.4%100.0%
Region
Name20242025vs 20242025 share
China23,024.4617,858.73-22.4%100.0%
Total23,024.4617,858.73-22.4%100.0%
Segment
Name20242025vs 20242025 share
Total Pharmaceutical Preparations revenue23,024.4617,858.73-22.4%100.0%
Total23,024.4617,858.73-22.4%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.77%0.0M0.5M804.59K
2026-10-155.61%0.0M0.5M766.28K
2026-09-308.12%0.0M0.5M890.39K
2026-09-1514.05%0.1M0.5M2.18M
2026-08-315.51%0.0M0.5M2.05M
2026-08-141.37%0.0M2.6M2.08M
2026-07-310.25%0.0M2.6M1.62M
2026-07-154.68%0.0M0.3M1.44M
2026-06-3072.57%0.2M0.3M1.30M
2026-06-153.53%0.0M0.3M20.06K
2026-05-293.20%0.0M0.3M8.63K
2026-05-153.97%0.0M0.3M8.69K
2026-04-300.14%0.0M0.6M8.52K
2026-04-150.84%0.0M0.6M9.27K
2026-03-310.85%0.0M0.6M14.44K
2026-03-130.86%0.0M0.6M76.11K
2026-02-272.39%0.0M0.6M90.16K
2026-02-131.61%0.0M0.6M92.23K
2026-01-302.12%0.0M0.6M91.15K
2026-01-151.71%0.0M0.6M92.84K

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-09EFFECTEffectiveness filing by commission orderSEC
2026-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-09-29F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-09-036-K/A2026-09-03SEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-01SCHEDULE 13GSEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-06-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-26SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-21SCHEDULE 13DSEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-04-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-16SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-02-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-11SEC
2026-01-2920-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-09-30SEC
2026-01-07SCHEDULE 13G/ASEC
2025-09-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP2.68%
GEODE CAPITAL MANAGEMENT, LLC0.89%
JANE STREET GROUP, LLC0.22%
OSAIC HOLDINGS, INC.0.12%
UBS Group AG0.03%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.93%

OakChart. UPC. Cached 15 minutes. Terms

Some panels did not load: ratings, insider.